Abbvie Inc (ABBV)

$248.84 +0.06 (0.02%)
Market Cap 453.11B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.59
Forward PE 18.25
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 1,234,213
Avg Vol 6,373,806
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 28%
Beta 0.29
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 9 at 7:01 PM
$SLS $ABBV $BMY 72nd Event Dec 26th 2025 +4.5 Months 78th Event May 11th 2026 4.5 Months for the Last 6 Events / 1 Event every 22.67 Days Its Now Been 121 Days Since the 78th Event .... ANY DAY NOW - We Will See the 80th Event and Share Price Launch. GPs is worth every nickel of $50B to big Pharma - this market rigged $14 /$2.8B Mcap will be a $28B Mcap / $140 Per Share and Climbing ... the instant the P3 Results are Announced. MARKTHISPOST
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 9 at 5:44 PM
$SLS $ABBV $BMY • GPs MOS 36 months CR2 AML vs BAT < 10 months $MRNA Added $40B in a Day Based on a 13.7 Month MOS for 2L Melanoma • this Rigged $13.90 Share Price $2.7BMCAP will be $139 and running as the market realizes GPs true value - treating 50,000 AML Remission Patients each year - and generating Tens of Billions of Dollars in Real Revenue. //
0 · Reply
Quantumup
Quantumup Sep. 9 at 11:42 AM
Guggenheim⬆️Top Pick $IDYA's PT to $57, stays Buy + provided its deep dive overview on the DLL3 landscape/previewed upcoming data for IDE849 (DLL3 TOP1I ADC) in 2H26—provided its R/R-Upside/Downside—updated Peak Sales. $AMGN AZN $ABBV ZLAB MRK - DSNKY AZN Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2097651514823061956?s=20
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 9 at 10:39 AM
$MRK $BMY $ABBV $RHHBY $NVS Under the radar Midcap Oncology Biotech TLK has PDUFA Date on the day after tomorrow (Friday). If Approved, TLK could go parabolic but no promises.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 9 at 5:03 AM
$SLS look at SLS since the Idmc unblinded actual MOS, Median Follow Up and IR data, from the Ongoing P3 for AML second remission CR2 maintenance. Pro tip: $ABBV $BMY the VIALE-M Oral Az Onureg+ Ven First Remission CR1 maintenance P3 FAILED. They know how their drugs / BAT for the SLS P3 Control arm, don’t work. They know its Gps doing what its done in EVERY PREVIOUS trial - prevent relapse and extend survival.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 8 at 11:48 PM
$SLS $MRNA Onureg / Oral Az is the only HMA proven to extend life. • Onureg MOS of 24.7 Months for FIRST REMISSION (CR1) • GPs Phase 2 MOS > 67.6 Months for FIRST REMISSION (CR2) $ABBV Combined Onureg w VEN in the VIALE-M Phase 3 Trial for AML FIRST REMISSION (CR1). • VIALE-M: Onureg + VEN Phase 3 Trial FAILED • VIALE-T: Onureg + VEN Phase 3 Trial for POST Transplant MAINTENANCE - also FAILED
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Sep. 8 at 11:32 PM
How Gilgamesh Turned On Big Pharma’s Billion-Dollar Appetite For Psychedelic Drugs: https://www.forbes.com/sites/willyakowicz/2026/09/04/how-gilgamesh-turned-on-big-pharmas-billion-dollar-appetite-for-psychedelic-drugs/ $ABBV
0 · Reply
Quantumup
Quantumup Sep. 8 at 6:03 PM
Jefferies⬆️ $TARS' PT to $105 from $88 and reiterated Buy. $ABBV NVS - ALC $BLTE ALC NBY Jefferies said in its note -- TARS stock has rallied post Q2 EPS on a combo of (1) increased Xdemvy 2026 guidance and recent scripts suggest a strong Q3; (2) Alkeus tuck-in for a Phase III-ready rare-disease asset injects new biotech pipeline into the narrative (we est $1B peak); and (3) iRenix deal for another Phase III asset. Valuation at $4B cap remains inexpensive over the long term, given multiple pipeline data-card flips over the next 1-3 years + strong Xdemvy base biz. PT to $105.
0 · Reply
VirtualCapital
VirtualCapital Sep. 8 at 5:07 PM
$ABBV The BCLI narrative is only about the trial but the numbers are so much worse. RMTG is just showing profits .
0 · Reply
Options_Destroyer
Options_Destroyer Sep. 8 at 3:01 PM
$ABBV added at open
0 · Reply
Latest News on ABBV
No data available.
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 9 at 7:01 PM
$SLS $ABBV $BMY 72nd Event Dec 26th 2025 +4.5 Months 78th Event May 11th 2026 4.5 Months for the Last 6 Events / 1 Event every 22.67 Days Its Now Been 121 Days Since the 78th Event .... ANY DAY NOW - We Will See the 80th Event and Share Price Launch. GPs is worth every nickel of $50B to big Pharma - this market rigged $14 /$2.8B Mcap will be a $28B Mcap / $140 Per Share and Climbing ... the instant the P3 Results are Announced. MARKTHISPOST
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 9 at 5:44 PM
$SLS $ABBV $BMY • GPs MOS 36 months CR2 AML vs BAT < 10 months $MRNA Added $40B in a Day Based on a 13.7 Month MOS for 2L Melanoma • this Rigged $13.90 Share Price $2.7BMCAP will be $139 and running as the market realizes GPs true value - treating 50,000 AML Remission Patients each year - and generating Tens of Billions of Dollars in Real Revenue. //
0 · Reply
Quantumup
Quantumup Sep. 9 at 11:42 AM
Guggenheim⬆️Top Pick $IDYA's PT to $57, stays Buy + provided its deep dive overview on the DLL3 landscape/previewed upcoming data for IDE849 (DLL3 TOP1I ADC) in 2H26—provided its R/R-Upside/Downside—updated Peak Sales. $AMGN AZN $ABBV ZLAB MRK - DSNKY AZN Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2097651514823061956?s=20
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 9 at 10:39 AM
$MRK $BMY $ABBV $RHHBY $NVS Under the radar Midcap Oncology Biotech TLK has PDUFA Date on the day after tomorrow (Friday). If Approved, TLK could go parabolic but no promises.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 9 at 5:03 AM
$SLS look at SLS since the Idmc unblinded actual MOS, Median Follow Up and IR data, from the Ongoing P3 for AML second remission CR2 maintenance. Pro tip: $ABBV $BMY the VIALE-M Oral Az Onureg+ Ven First Remission CR1 maintenance P3 FAILED. They know how their drugs / BAT for the SLS P3 Control arm, don’t work. They know its Gps doing what its done in EVERY PREVIOUS trial - prevent relapse and extend survival.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 8 at 11:48 PM
$SLS $MRNA Onureg / Oral Az is the only HMA proven to extend life. • Onureg MOS of 24.7 Months for FIRST REMISSION (CR1) • GPs Phase 2 MOS > 67.6 Months for FIRST REMISSION (CR2) $ABBV Combined Onureg w VEN in the VIALE-M Phase 3 Trial for AML FIRST REMISSION (CR1). • VIALE-M: Onureg + VEN Phase 3 Trial FAILED • VIALE-T: Onureg + VEN Phase 3 Trial for POST Transplant MAINTENANCE - also FAILED
1 · Reply
LibertarianTreehugger
LibertarianTreehugger Sep. 8 at 11:32 PM
How Gilgamesh Turned On Big Pharma’s Billion-Dollar Appetite For Psychedelic Drugs: https://www.forbes.com/sites/willyakowicz/2026/09/04/how-gilgamesh-turned-on-big-pharmas-billion-dollar-appetite-for-psychedelic-drugs/ $ABBV
0 · Reply
Quantumup
Quantumup Sep. 8 at 6:03 PM
Jefferies⬆️ $TARS' PT to $105 from $88 and reiterated Buy. $ABBV NVS - ALC $BLTE ALC NBY Jefferies said in its note -- TARS stock has rallied post Q2 EPS on a combo of (1) increased Xdemvy 2026 guidance and recent scripts suggest a strong Q3; (2) Alkeus tuck-in for a Phase III-ready rare-disease asset injects new biotech pipeline into the narrative (we est $1B peak); and (3) iRenix deal for another Phase III asset. Valuation at $4B cap remains inexpensive over the long term, given multiple pipeline data-card flips over the next 1-3 years + strong Xdemvy base biz. PT to $105.
0 · Reply
VirtualCapital
VirtualCapital Sep. 8 at 5:07 PM
$ABBV The BCLI narrative is only about the trial but the numbers are so much worse. RMTG is just showing profits .
0 · Reply
Options_Destroyer
Options_Destroyer Sep. 8 at 3:01 PM
$ABBV added at open
0 · Reply
V9RDPUMA
V9RDPUMA Sep. 8 at 2:26 PM
$ABBV WTF is the problem now?
0 · Reply
Beamen216
Beamen216 Sep. 8 at 1:39 PM
$ABBV per previous convos. Follow me for more random thoughts that might make you some money, will probably lose you some money
0 · Reply
biolover
biolover Sep. 7 at 7:48 PM
$VKTX New observations from $NVO CEO repeated mentioning of GIP - novo realized what is missing - and first time he talks about partnering with others and not just M&A ? He acknowledges need for “ earlier launched assets than us “. Will get interesting next few weeks. $ABBV and others watching all that. https://finance.yahoo.com/video/weight-loss-just-beginning-glp-100000472.html?contentType=VIDEO
4 · Reply
DividendPower
DividendPower Sep. 5 at 6:42 PM
The 2026 Dividend Kings: A Complete List and Analysis - Updated 09/05/26 $FUL $UVV $CL $ABBV $WMT https://www.dividendpower.org/2026-dividend-kings/
0 · Reply
Pope_of_Profit
Pope_of_Profit Sep. 4 at 6:58 PM
$ABBV needs to go below (a)
0 · Reply
prismmarketview
prismmarketview Sep. 4 at 2:54 PM
$ABBV AbbVie’s investigational etentamig met dual primary endpoints in the Phase 3 CERVINO study in triple-class-exposed relapsed/refractory multiple myeloma. The therapy delivered a 74% objective response rate and reduced the risk of progression or death by 60% versus standard available treatments. https://prismmarketview.com/abbvies-etentamig-shows-strong-results-in-phase-3-blood-cancer-study/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 1:25 PM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 1:02 PM
$SLS $MRNA 2025 REGAL Interim Analysis was announced -- 60 Events. $.9 / $1.0 share price at the time - Jumped to $1.70 Including 50M shares of Dilution. Mcap increased 3x ... in a week after the Interim. Added Cash / warrants.... • the Share PRICE Started Climbing - along with funds invested, cash on hand, BAT Phase 3 Trial Failures, Market cap up more than the Share Price. • ALL SINCE THE IDMC UNBLINDED ACTUAL PHASE 3 MOS and Confirmatory Immune Response DATA • that told Smarter Money than most of US -- GPS is reason we are seeing Miraculous Extended Survival. $ABBV $BMY who own Aza VEN - Know ... and many many others Holding the 200M share float. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 12:59 PM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 8:12 AM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. just like the last times. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
1 · Reply
Techdamentals
Techdamentals Sep. 4 at 3:31 AM
$ABBV at a 52-week high. $260 now. Find out what it is actually worth 👇 https://techdamentals.com/v/ABBV?ref=st
0 · Reply
DidYouReadThis
DidYouReadThis Sep. 4 at 12:27 AM
$ABBV
0 · Reply